Stay updated on Pembrolizumab Combo in Small Cell Lung Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo in Small Cell Lung Cancer Clinical Trial page.

Latest updates to the Pembrolizumab Combo in Small Cell Lung Cancer Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoNo Change Detected
- Check18 days agoChange DetectedThe revision label on the page updates from v3.6.3 to v3.6.4, indicating a new minor version of the page/document.SummaryDifference0.0%

- Check25 days agoNo Change Detected
- Check39 days agoChange DetectedRevision changed from v3.6.0 to v3.6.3, updating the page's version identifier. This indicates that a newer revision of the page has been published.SummaryDifference0.0%

- Check61 days agoChange DetectedNew navigation items and guidance sections appear, including How to Read a Study Record, Common Questions, and How to Join a Study, with an explicit recruitment status update indicating no participants are being sought. The Intervention/Treatment label is reformatted and a new revision tag v3.6.0 replaces the prior version tag.SummaryDifference0.2%

- Check68 days agoChange Detected- The page revision was updated from v3.5.4 to v3.5.5, signaling a minor update to the publication. The overall study information remains unchanged.SummaryDifference0.0%

- Check82 days agoChange DetectedRevision: v3.5.4 has been added, replacing the previous Revision: v3.5.3. This signals a minor revision to the page's revision history, typically for maintenance or tracking, and does not change the study details.SummaryDifference0.0%

- Check104 days agoChange DetectedA new page revision tag v3.5.3 was added to update the version history, and the older revision tag v3.5.0 was removed.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab Combo in Small Cell Lung Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in Small Cell Lung Cancer Clinical Trial page.